Home » Stocks » VIRI

Virios Therapeutics, Inc. (VIRI)

Virios Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $9.00 - $11.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 78.32M
Revenue (ttm) n/a
Net Income (ttm) -2.57M
Shares Out 7.83M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 78.32M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.83M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.33
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield -3.28%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -2.57M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in USD.

Financial Overview

Year20192018
Revenue00
Net Income / Loss-2,473,000-2,113,000
Numbers in USD.

Company Profile

Company Details

Full Name Virios Therapeutics, Inc.
Country United States
Employees 4
CEO Greg Duncan

Stock Information

Ticker Symbol VIRI
Stock Exchange NASDAQ
Unique Identifier NASDAQ: VIRI
IPO Date Pending

Description

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate (“IMC-1”), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.